UNSPSC 51131904: Human blood plasma

This classification denotes a protein-based fluid (sometimes also called simulated body fluid) or that residual portion of blood that is left after removal of blood cells by centrifugation without prior blood coagulation, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 839MOZ74GK. European Medicines Agency schedules Human Blood Plasma in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB51727.

UNSPSC 51131904 Human blood plasma, a Commodity code, covers procurement of blood plasma — the liquid component of blood separated from cells — for transfusion, therapeutic use, or manufacturing purposes in state and local health systems and medical facilities. State and local governments purchase plasma under this code for hospital transfusion services, emergency departments, surgical support, and specialty treatment protocols where plasma replacement or clotting factor therapy is clinically indicated. Issuing bodies include state health departments, county hospitals, municipal medical centers, and independent hospital districts that operate their own blood banks or work through blood supplier networks and cooperative purchasing arrangements.

The source provides no recent state and local opportunities tagged to this code, leaving geographic concentration and current market activity undefined. State and local procurement officials and business development professionals tracking this code should monitor health procurement portals in states with large hospital systems and blood-banking infrastructure — particularly those with state-operated medical centers or regional health authorities — for RFPs and ITBs from hospital purchasing consortia, which commonly solicit plasma supplies on fixed or on-demand schedules.